[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 37 of about 37
1. Ogiuchi Y, Maruoka Y, Ando T, Kobayashi M, Ogiuchi H: Thymidylate synthase, thymidine phosphorylase and orotate phosphoribosyl transferase levels as predictive factors of chemotherapy in oral squamous cell carcinoma. Acta Histochem Cytochem; 2008 Jun 27;41(3):39-46
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymidylate synthase, thymidine phosphorylase and orotate phosphoribosyl transferase levels as predictive factors of chemotherapy in oral squamous cell carcinoma.
  • We conducted a clinicopathologic study on protein and mRNA levels of thymidylate synthase (TS), thymidine phosphorylase (TP) and orotate phosphoribosyl transferase (OPRT) using biopsy tissue specimens before treatment.
  • The mRNA levels have been measured in tumor cells microdissected from paraffin-embedded specimens (Danenberg Tumor Profile method: DTP method).
  • We studied the mRNA and protein expression as effect predictive factors in chemotherapy.
  • The subjects consisted of 20 cases of untreated oral squamous cell carcinoma who had undergone chemotherapy with TS-1 (16 males and 4 females, tongue in 8 cases, upper gingiva in 3 cases, lower gingiva in 3 cases, buccal mucosa in 5 cases and floor of the mouth in 1 case).
  • Furthermore, regarding males who were less than 70 years of age, stage I and II, well differentiated type and tongue, TS mRNA expression of the responders were lower than that for the nonresponders.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2003 Oct 20;89(8):1486-92 [14562021.001]
  • [Cites] Oncol Rep. 2006 Jun;15(6):1417-23 [16685374.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002 Dec;94(6):717-23 [12464897.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):42-9 [10618604.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2371-6 [9796967.001]
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3223-9 [9336359.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):176-82 [8558194.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Acta Otolaryngol. 2006 Dec;126(12):1295-302 [17101591.001]
  • [Cites] Int J Oral Maxillofac Surg. 2006 Mar;35(3):265-9 [16257511.001]
  • [Cites] Br J Cancer. 2005 Oct 17;93(8):884-9 [16189518.001]
  • [Cites] Oral Oncol. 2005 Mar;41(3):276-82 [15743690.001]
  • [Cites] J Am Coll Surg. 2005 Mar;200(3):336-44 [15737843.001]
  • [Cites] Br J Cancer. 2004 Oct 4;91(7):1245-50 [15354215.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4116-24 [14519634.001]
  • [Cites] Oral Oncol. 2006 Oct;42(9):880-7 [16757204.001]
  • [Cites] Int J Cancer. 2004 Dec 20;112(6):967-73 [15316940.001]
  • (PMID = 18636111.001).
  • [ISSN] 0044-5991
  • [Journal-full-title] Acta histochemica et cytochemica
  • [ISO-abbreviation] Acta Histochem Cytochem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Other-IDs] NLM/ PMC2447914
  • [Keywords] NOTNLM ; oral cancer / orotate phosphoribosyl transferase / thymidine phosphorylase / thymidylate synthase
  •  go-up   go-down


2. Loprevite M, Tiseo M, Chiaramondia M, Capelletti M, Bozzetti C, Bortesi B, Naldi N, Nizzoli R, Dadati P, Kunkl A, Zennaro D, Lagrasta C, Campanini N, Spiritelli E, Camisa R, Grossi F, Rindi G, Franciosi V, Ardizzoni A: Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer. Clin Cancer Res; 2007 Nov 1;13(21):6518-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer.
  • PURPOSE: To evaluate the role of pretreatment and posttreatment expression in buccal mucosa cells of signal transduction proteins activated by epidermal growth factor receptor, including phosphorylated epidermal growth factor receptor (p-EGFR), phosphorylated mitogen-activated protein kinase (p-MAPK), and phosphorylated AKT (p-AKT), in predicting gefitinib activity in advanced non-small cell lung cancer patients.
  • Expression of the same proteins was also assessed on corresponding tissue samples for comparison.
  • EXPERIMENTAL DESIGN: Protein expression was evaluated by standard immunocytochemistry in buccal smears, obtained by scraping immediately before and after 2 weeks of gefitinib treatment, and in the available archival tumor specimens.
  • Toxicity (P = 0.025) and baseline p-AKT expression in buccal mucosa cells (P = 0.061) showed a potential predictive role.
  • On the contrary, the probability of achieving an objective response was not affected by pretreatment expression of EGFR, p-EGFR, and p-MAPK, either in buccal mucosa or in tumor tissue.
  • Responders showed a nonstatistically significant trend toward a more pronounced reduction in the expression of p-EGFR, p-MAPK, and p-AKT after gefitinib treatment.
  • CONCLUSIONS: Epithelial cells obtained from buccal mucosa may be used to assess the pharmacodynamic effect of EGFR-targeted agents, and pretreatment p-AKT expression may be a possible predictive biomarker of in vivo gefitinib activity.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Non-Small-Cell Lung / drug therapy. Drug Screening Assays, Antitumor / methods. Lung Neoplasms / drug therapy. Mouth Mucosa / cytology. Mouth Mucosa / metabolism. Quinazolines / pharmacology
  • [MeSH-minor] Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry / methods. MAP Kinase Signaling System. Phosphorylation. Proto-Oncogene Proteins c-akt / metabolism. Proto-Oncogene Proteins p21(ras) / metabolism. Receptor, Epidermal Growth Factor / metabolism. Signal Transduction. Time Factors

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17975165.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.6.5.2 / Proto-Oncogene Proteins p21(ras); S65743JHBS / gefitinib
  •  go-up   go-down


3. Attia S, Kolesar J, Mahoney MR, Pitot HC, Laheru D, Heun J, Huang W, Eickhoff J, Erlichman C, Holen KD: A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas. Invest New Drugs; 2008 Aug;26(4):369-79
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Therefore, the Phase 2 Consortium (P2C) initiated a trial (two single stage studies with planned interim analysis) of 3-AP at 96 mg/m(2) intravenously days 1-4 and 15-18 of a 28-day cycle in both chemotherapy-naive and gemcitabine-refractory (GR) patients with advanced pancreatic cancer.
  • The primary endpoint was survival at six months (chemotherapy-naive) and four months (GR).
  • Secondary endpoints were toxicity, response, overall survival, time to progression and mechanistic studies.
  • Fifteen patients were enrolled including one chemotherapy-naïve and 14 GR.
  • The chemotherapy-naïve patient progressed during cycle 1 with grade 3 and 4 toxicities.
  • Progression precluded further treatment in 11 GR patients.
  • Additionally, one died of an ileus in cycle 1 considered related to treatment and two stopped treatment due to toxicity.
  • Correlative studies confirmed that 3-AP increased the percentage of S-phase buccal mucosal cells, the presence of multidrug resistance gene polymorphisms appeared to predict leukopenia, and baseline pancreatic tumor RR M2 expression was low relative to other tumors treated with 3-AP.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18278438.001).
  • [ISSN] 0167-6997
  • [Journal-full-title] Investigational new drugs
  • [ISO-abbreviation] Invest New Drugs
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006973; United States / NCI NIH HHS / CM / N01 CM062205; United States / NCI NIH HHS / CM / N01 CM-62205; United States / PHS HHS / / 1ULIRR025011; United States / NCRR NIH HHS / RR / UL1 RR025011; United States / NCI NIH HHS / CA / T32 CA009614; United States / PHS HHS / / 24XS090
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Pyridines; 0 / Thiosemicarbazones; 0W860991D6 / Deoxycytidine; 143621-35-6 / 3-aminopyridine-2-carboxaldehyde thiosemicarbazone; B76N6SBZ8R / gemcitabine; EC 1.17.4.- / ribonucleotide reductase M2; EC 1.17.4.1 / Ribonucleoside Diphosphate Reductase
  • [Other-IDs] NLM/ NIHMS692508; NLM/ PMC4461052
  •  go-up   go-down


Advertisement
4. Wang HM, Ng SH, Wang CH, Liaw CT, Chen JS, Yang TS, Chen IH: Intra-arterial plus i.v. chemotherapy for advanced bulky squamous cell carcinoma of the buccal mucosa. Anticancer Drugs; 2001 Apr;12(4):331-7
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-arterial plus i.v. chemotherapy for advanced bulky squamous cell carcinoma of the buccal mucosa.
  • From July 1994 to December 1996, 41 patients with previously untreated, advanced bulky squamous cell carcinoma arising from the buccal mucosa (BSCC) were enrolled.
  • The tumor extent was stage III/IV: three of 38, T4: 85%, N2-3: 20%.
  • Patients were initially scheduled to receive intra-arterial (i.a.) chemotherapy, followed by i.v. chemotherapy and regional therapy.
  • The i.a. chemotherapy catheter was properly placed by external carotid artery angiography via the femoral artery.
  • The i.a. chemotherapy consisted of cisplatin (P) 100 mg/m(2) day 1 plus 5-fluorouracil (F) 1000 mg/m(2) day 1-4, and the i.v. chemotherapy consisted of PF (10 patients) or PF plus methotrexate 200 mg/m(2) day 15 and 22 (31 patients).
  • All chemotherapy regimens were administered at 4-week intervals.
  • The response rate of i.a. plus i.v. chemotherapy for the primary site was 85% (35 of 41) with 29% complete remission (CR) (12 of 41).
  • Major toxicity from i.a. chemotherapy of WHO grade > or = 3 included: mucositis of infusion area (76%), hemialopecia (56%) and leukopenia (5%).
  • Three neurologic complications of i.a. chemotherapy including one hemiparesis occurred.
  • The median follow-up time was 47 months (range 36-66 months), and the overall survival and disease-free survival were both 34% (14 of 41).
  • Four patients were cured with chemotherapy alone and eight patients (19.5%) were cured without surgical intervention.
  • Using i.a. chemotherapy as a cytoreductive therapy followed by subsequent i.v. chemotherapy produces a high response rate and an encouraging degree of complete response rate in advanced bulky BSCC.
  • However, toxicity management and catheter placement will need to be improved in order to better define the role of this therapy in advanced BSCC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Alopecia / chemically induced. Cisplatin / administration & dosage. Drug Administration Schedule. Drug Eruptions / etiology. Dyspnea / chemically induced. Dyspnea / drug therapy. Fluorouracil / administration & dosage. Humans. Infusions, Intra-Arterial / methods. Infusions, Intravenous / methods. Lymphatic Metastasis. Male. Methotrexate / administration & dosage. Middle Aged. Mouth Mucosa. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Radiotherapy, Adjuvant. Stomatitis / chemically induced. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11335789.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


5. Adjei AA, Croghan GA, Erlichman C, Marks RS, Reid JM, Sloan JA, Pitot HC, Alberts SR, Goldberg RM, Hanson LJ, Bruzek LM, Atherton P, Thibault A, Palmer PA, Kaufmann SH: A Phase I trial of the farnesyl protein transferase inhibitor R115777 in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin Cancer Res; 2003 Jul;9(7):2520-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Toxicities were graded by the National Cancer Institute Common Toxicity Criteria and recorded as maximum grade per patient for each treatment cycle.
  • At the maximum tolerated dose, accumulation of prelamin A in buccal mucosa cells of patients was evaluated as a marker of farnesyl transferase inhibition by R115777.
  • At the maximum tolerated dose, defined as R115777 300 mg twice daily p.o., 1000 mg/m(2) gemcitabine, and 75 mg/m(2) cisplatin, inhibition of prelamin A farnesylation in buccal mucosa cells of patients was demonstrated, confirming that R115777 inhibits protein farnesylation in vivo.
  • This combination warrants further evaluation in a number of tumor types.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Enzyme Inhibitors / therapeutic use. Neoplasms / drug therapy. Quinolones / administration & dosage
  • [MeSH-minor] Adult. Aged. Alkyl and Aryl Transferases / antagonists & inhibitors. Dose-Response Relationship, Drug. Electrolytes. Farnesyltranstransferase. Female. Humans. Immunohistochemistry. Male. Maximum Tolerated Dose. Middle Aged. Mouth Mucosa / metabolism. Time Factors

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12855626.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01 CA069912; United States / NCI NIH HHS / CA / CA69912; United States / NCRR NIH HHS / RR / RR00585
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Electrolytes; 0 / Enzyme Inhibitors; 0 / Quinolones; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 2.5.- / Alkyl and Aryl Transferases; EC 2.5.1.29 / Farnesyltranstransferase; MAT637500A / tipifarnib; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


6. Tan AR, Yang X, Berman A, Zhai S, Sparreboom A, Parr AL, Chow C, Brahim JS, Steinberg SM, Figg WD, Swain SM: Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer. Clin Cancer Res; 2004 Aug 1;10(15):5038-47
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ki67, p53, and phosphorylated retinoblastoma protein (phospho-Rb) in paired tumor and buccal mucosa biopsies (obtained pre- and posttreatment) were examined by immunohistochemistry.
  • Nuclear staining with p53 increased and phospho-Rb decreased in 10 pairs of buccal mucosa biopsies posttreatment (P = 0.002 and P = 0.04, respectively).
  • The changes in p53 and phospho-Rb in buccal mucosa suggest that a biological effect with flavopiridol was achieved.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Cyclin-Dependent Kinases / antagonists & inhibitors. Enzyme Inhibitors / administration & dosage. Flavonoids / administration & dosage. Piperidines / administration & dosage. Taxoids / administration & dosage
  • [MeSH-minor] Adult. Aged. Area Under Curve. Biomarkers, Tumor / metabolism. Biopsy. Clinical Trials as Topic. Female. Humans. Immunohistochemistry. Ki-67 Antigen / biosynthesis. Middle Aged. Mouth Mucosa / pathology. Mucous Membrane / pathology. Neoplasm Metastasis. Phosphorylation. Retinoblastoma Protein / biosynthesis. Time Factors. Tumor Suppressor Protein p53 / metabolism

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15297405.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Enzyme Inhibitors; 0 / Flavonoids; 0 / Ki-67 Antigen; 0 / Piperidines; 0 / Retinoblastoma Protein; 0 / Taxoids; 0 / Tumor Suppressor Protein p53; 15H5577CQD / docetaxel; 45AD6X575G / alvocidib; EC 2.7.11.22 / Cyclin-Dependent Kinases
  •  go-up   go-down


7. Hoebers FJ, Pluim D, Hart AA, Verheij M, Balm AJ, Fons G, Rasch CR, Schellens JH, Stalpers LJ, Bartelink H, Begg AC: Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor. Cancer Chemother Pharmacol; 2008 May;61(6):1075-81
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cisplatin-DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor.
  • PURPOSE: In this study, the formation of cisplatin-DNA adducts after concurrent cisplatin-radiation and the relationship between adduct-formation in primary tumor tissue and normal tissue were investigated.
  • A (32)P-postlabeling technique was used to quantify adducts in normal tissue [white blood cells (WBC) and buccal cells] and tumor.
  • RESULTS: Normal tissue samples for adduct determination were obtained from 63 patients and tumor biopsies from 23 of these patients.
  • Linear relationships and high correlations were observed between the levels of two guanosine- and adenosine-guanosine-adducts in normal and tumor tissue.
  • Adduct levels in tumors were two to five times higher than those in WBC (P<0.001).
  • No significant correlations were found between adduct levels in normal tissues and primary tumor biopsies, nor between WBC and buccal cells.
  • CONCLUSIONS: In concurrent chemoradiotherapy schedules, cisplatin adduct levels in tumors were significantly higher than in normal tissues (WBC).
  • No evidence of a correlation was found between adduct levels in normal tissues and primary tumor biopsies.
  • This lack of correlation may, to some extent, explain the inconsistencies in the literature regarding whether or not cisplatin-DNA adducts can be used as a predictive test in anticancer platinum therapy.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Cisplatin / adverse effects. DNA Adducts / drug effects. Neoplasms / metabolism
  • [MeSH-minor] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / radiotherapy. Combined Modality Therapy. Head and Neck Neoplasms / drug therapy. Head and Neck Neoplasms / metabolism. Head and Neck Neoplasms / radiotherapy. Humans. Leukocyte Count. Mouth Mucosa / cytology. Predictive Value of Tests

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Jan;79(1):82-8 [10408697.001]
  • [Cites] N Engl J Med. 2006 Sep 7;355(10):983-91 [16957145.001]
  • [Cites] Int J Cancer. 2006 Aug 15;119(4):750-6 [16550603.001]
  • [Cites] Anal Biochem. 1999 Nov 1;275(1):30-8 [10542106.001]
  • [Cites] J Clin Oncol. 2000 Apr;18(7):1458-64 [10735893.001]
  • [Cites] Int J Cancer. 2000 Mar 20;89(2):160-6 [10754494.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] Lancet. 2001 Sep 8;358(9284):781-6 [11564482.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2992-9 [12231546.001]
  • [Cites] Clin Pharmacol Ther. 2003 May;73(5):417-26 [12732842.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] Eur J Cancer Clin Oncol. 1986 Mar;22(3):257-63 [3709595.001]
  • [Cites] Radiother Oncol. 1986 May;6(1):61-74 [3715061.001]
  • [Cites] Int J Radiat Biol Relat Stud Phys Chem Med. 1986 Nov;50(5):871-84 [3490450.001]
  • [Cites] Cancer Res. 1987 Jun 1;47(11):3000-4 [3552211.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Jul;84(14):5024-8 [3110781.001]
  • [Cites] Cancer Res. 1987 Nov 15;47(22):6134-7 [3664513.001]
  • [Cites] Carcinogenesis. 1988 Oct;9(10):1909-11 [2458857.001]
  • [Cites] Cancer Res. 1990 Jun 15;50(12):3556-61 [2340504.001]
  • [Cites] Cancer Res. 1990 Dec 15;50(24):7887-94 [2253228.001]
  • [Cites] Cancer. 1991 Jun 1;67(11):2828-32 [2025848.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1993 Jun;119(6):612-7 [8499090.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1993 May-Jun;2(3):229-34 [8318875.001]
  • [Cites] Cancer Res. 1993 Dec 1;53(23):5669-75 [8242622.001]
  • [Cites] Cancer. 1994 Jun 1;73(11):2843-52 [7514956.001]
  • [Cites] Br J Cancer. 1995 Mar;71(3):512-7 [7880732.001]
  • [Cites] Carcinogenesis. 1995 Oct;16(10):2447-53 [7586150.001]
  • [Cites] Cancer Chemother Pharmacol. 1995;37(1-2):23-31 [7497593.001]
  • [Cites] Cancer Chemother Pharmacol. 1995;37(1-2):150-4 [7497585.001]
  • [Cites] Br J Cancer. 1996 Jun;73(12):1569-75 [8664132.001]
  • [Cites] Int J Cancer. 1996 Nov 15;68(4):452-6 [8945615.001]
  • [Cites] N Engl J Med. 1998 Jun 18;338(25):1798-804 [9632446.001]
  • [Cites] Clin Cancer Res. 1996 Jun;2(6):1063-6 [9816268.001]
  • [Cites] Clin Cancer Res. 1996 Nov;2(11):1829-35 [9816137.001]
  • [Cites] N Engl J Med. 1999 Apr 15;340(15):1154-61 [10202166.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1963-71 [16287073.001]
  • (PMID = 17639394.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA Adducts; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ PMC2270367
  •  go-up   go-down


8. Tsurumaru D, Kuroiwa T, Yabuuchi H, Hirata H, Higaki Y, Tomita K: Efficacy of intra-arterial infusion chemotherapy for head and neck cancers using coaxial catheter technique: initial experience. Cardiovasc Intervent Radiol; 2007 Mar-Apr;30(2):207-11
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of intra-arterial infusion chemotherapy for head and neck cancers using coaxial catheter technique: initial experience.
  • The aim of this study was to evaluate the efficacy of intra-arterial infusion chemotherapy for head and neck cancers using a coaxial catheter technique: the superficial temporal artery (STA)-coaxial catheter method.
  • Thirty-one patients (21 males and 10 females; 37-83 years of age) with squamous cell carcinoma of the head and neck (maxilla, 2; epipharynx, 4; mesopharynx, 8; oral floor, 4; tongue, 10; lower gingiva, 1; buccal mucosa, 2) were treated by intra-arterial infusion chemotherapy.
  • Four patients were excluded from the tumor-response evaluation because of a previous operation or impossibility of treatment due to catheter trouble.
  • A guiding catheter was inserted into the STA and a microcatheter was advanced into the tumor-feeding artery via the guiding catheter under angiographic guidance.
  • When the location of the tumor or its feeding artery was uncertain on angiography, computed tomographic angiography was performed.
  • External radiotherapy was administered during intra-arterial chemotherapy at a total dose of 21-70.5 Gy.
  • Injury and dislocation of the microcatheter occurred 10 times in 7 patients.
  • Catheter infection was observed three times in each of two patients, and catheter occlusion and vasculitis occurred in two patients.
  • Intra-arterial infusion chemotherapy via the STA-coaxial catheter method could have potential as a favorable treatment for head and neck tumors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carboplatin / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Catheterization, Peripheral / methods. Head and Neck Neoplasms / drug therapy. Infusions, Intra-Arterial
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Area Under Curve. Brachytherapy. Female. Humans. Male. Middle Aged. Radiotherapy, Adjuvant. Temporal Arteries. Treatment Outcome. Tumor Burden / drug effects. Tumor Burden / radiation effects

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17216381.001).
  • [ISSN] 0174-1551
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; BG3F62OND5 / Carboplatin
  •  go-up   go-down


9. Grau JJ, Domingo J, Blanch JL, Verger E, Castro V, Nadal A, Alós L, Estapé J: Multidisciplinary approach in advanced cancer of the oral cavity: outcome with neoadjuvant chemotherapy according to intention-to-treat local therapy. A phase II study. Oncology; 2002;63(4):338-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidisciplinary approach in advanced cancer of the oral cavity: outcome with neoadjuvant chemotherapy according to intention-to-treat local therapy. A phase II study.
  • OBJECTIVES: To determine outcomes in local-regional control and overall survival in patients with squamous locally advanced cancer of the oral cavity, based on intention-to-treat with neoadjuvant chemotherapy followed by surgery or radiation therapy.
  • All had squamous cell carcinomas of the oral cavity in stage III or in nonmetastatic stage IV and were selected for surgery or radiation therapy (if located in the tonsils or in the base of the tongue).
  • Chemotherapy was based on cisplatin 120 mg/m(2) i.v. day 1 plus bleomycin 20 mg/m(2) days 1-5 in continuous i.v. perfusion or plus 5-fluorouracil 1,000 mg/m(2) days 1-5 in continuous i.v. perfusion.
  • Definitive surgery (n = 73; plus adjuvant radiation therapy) or definitive radiation therapy (n = 131) was performed.
  • RESULTS: One hundred thirty-five out of 204 (66%) patients were chemotherapy responders, 16% complete and 50% partial.
  • One hundred ninety-four patients (95%) completed 2 courses of chemotherapy.
  • After neoadjuvant chemotherapy, 34 out of 46 patients considered inoperable initially (74%) obtained a disease-free status with surgery.
  • Eighty-three percent of surgical patients obtained a disease-free status (initial tumor control) versus 72% of radiation therapy patients.
  • A better prognosis was observed in stage III over IV (p = 0.02); primary tumor in the retromolar trigone, palate or buccal mucosa over tongue, tonsil or floor of the mouth (p = 0.0085); negative cervical nodes over positive (p = 0.0186); responders to chemotherapy over nonresponders (p = 0.0003); and adjuvant postsurgical radiation therapy (p = 0.0013).
  • CONCLUSIONS: In locally advanced squamous cell carcinoma of the oral cavity, neoadjuvant chemotherapy induces a high response rate that may facilitate definitive surgery or radiotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Bleomycin / administration & dosage. Cisplatin / administration & dosage. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Staging. Survival Analysis

  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 S. Karger AG, Basel
  • (PMID = 12417788.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


10. Yamamoto K, Obara S, Mishima K, Nakamura H, Yoshimura Y: [An advanced case of squamous cell carcinoma in the left buccal mucosa, upper gingiva, and maxillary sinus (T4N0M0) showing a complete response to chemotherapy with TS-1]. Gan To Kagaku Ryoho; 2004 Apr;31(4):635-7
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An advanced case of squamous cell carcinoma in the left buccal mucosa, upper gingiva, and maxillary sinus (T4N0M0) showing a complete response to chemotherapy with TS-1].
  • We report a case of advanced squamous cell carcinoma in the left buccal mucosa, upper gingiva, and maxillary sinus (T4N0M0) showing a complete response to oral chemotherapy with TS-1.
  • We carried out chemotherapy with TS-1 50 mg/day, without surgical treatment.
  • The tumor disappeared clinically at 4 months after 3 courses of the TS-1 administration.
  • Adverse drug reactions, including vomiting, leukopenia and thrombopenia, forced a stop of the administration of TS-1.
  • Although she finally died of in senescence 2 months from the cease of administration, there was no recurrence of the cancer at the time.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / pathology. Gingival Neoplasms / pathology. Maxillary Sinus Neoplasms / pathology. Mouth Neoplasms / drug therapy. Mouth Neoplasms / pathology. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Drug Administration Schedule. Drug Combinations. Female. Humans. Leukopenia / chemically induced. Mouth Mucosa / pathology. Neoplasm Invasiveness. Remission Induction. Thrombocytopenia / chemically induced. Vomiting, Anticipatory / etiology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15114716.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


11. Giannola LI, De Caro V, Giandalia G, Siragusa MG, Paderni C, Campisi G, Florena AM: 5-Fluorouracil buccal tablets for locoregional chemotherapy of oral squamous cell carcinoma: formulation, drug release and histological effects on reconstituted human oral epithelium and porcine buccal mucosa. Curr Drug Deliv; 2010 Apr;7(2):109-17
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 5-Fluorouracil buccal tablets for locoregional chemotherapy of oral squamous cell carcinoma: formulation, drug release and histological effects on reconstituted human oral epithelium and porcine buccal mucosa.
  • 5-Fluorouracil (5-FU) is currently used for treatment of oral squamous cell carcinoma (OSCC).
  • 5-FU is given by i.v. although the systemic administration is associated with severe toxic effects and no topical formulations of 5-FU for buccal drug delivery have been reported.
  • In this study we would report the development of buccal tablets suitable for direct application of low-doses of 5-FU on cancer lesions.
  • The topical administration could be effective on tumor area while systemic undesired side effects are avoided.
  • Preliminarily, the limited tendency of 5-FU to cross the buccal tissue was established using reconstituted human oral epithelium (RHOE, in vitro) and porcine buccal mucosa (ex vivo) as mucosal models.
  • Matrix buccal tablets, were designed for 5-FU local delivery, developed and prepared.
  • Release tests showed a highly reproducible Higuchian drug discharge.
  • After tablet administration on buccal tissue specimens, the occurrence of histo-morphological effects of 5-FU was highlighted.
  • Apoptotic events were registered in all samples treated while only negligible amounts of 5-FU permeated the buccal membrane and reached the simulated plasma.
  • The results suggest that loaded matrix tablets containing 5% of 5-FU could be a useful means in topical treatment of OSCC.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Chemistry, Pharmaceutical / methods. Fluorouracil / administration & dosage. Mouth Neoplasms / drug therapy. Tablets / administration & dosage
  • [MeSH-minor] Administration, Buccal. Animals. Apoptosis / drug effects. Drug Compounding / methods. Drug Delivery Systems / methods. Humans. Mouth Mucosa / anatomy & histology. Mouth Mucosa / drug effects. Permeability. Swine. Tissue Culture Techniques

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20158481.001).
  • [ISSN] 1875-5704
  • [Journal-full-title] Current drug delivery
  • [ISO-abbreviation] Curr Drug Deliv
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Tablets; U3P01618RT / Fluorouracil
  •  go-up   go-down


12. Nashida Y, Yamakado K, Kumamoto T, Suga S, Takaki H, Hori H, Azuma E, Komada Y: Radiofrequency ablation used for the treatment of frequently recurrent rhabdomyosarcoma in the masticator space in a 10-year-old girl. J Pediatr Hematol Oncol; 2007 Sep;29(9):640-2
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation used for the treatment of frequently recurrent rhabdomyosarcoma in the masticator space in a 10-year-old girl.
  • Radiofrequency (RF) ablation was performed for the treatment of recurrent rhabdomyosarcoma in a 10-year-old girl.
  • The tumor measuring 2.4 cm in a maximum diameter was in the right masticator space and invaded the buccal mucosa at the time of third local relapse after surgical intervention, chemotherapy, radiotherapy, and photodynamic therapy.
  • The RF electrode was placed into the center of the tumor with the computed tomography fluoroscopic guide under general anesthesia.
  • Tumor enhancement disappeared on contrast-enhanced magnetic resonance images after RF ablation.
  • The tumor deciduated into the oral cavity 34 days after RF ablation showing apoptosis throughout the tumor on histologic study.
  • Buccal mucosal injury cured but she suffered from trismus.
  • The tumor has completely disappeared for 18 months after RF ablation.
  • [MeSH-minor] Child. Disease-Free Survival. Female. Humans. Mouth Mucosa / pathology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17805041.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Lo WL, Kao SY, Chi LY, Wong YK, Chang RC: Outcomes of oral squamous cell carcinoma in Taiwan after surgical therapy: factors affecting survival. J Oral Maxillofac Surg; 2003 Jul;61(7):751-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of oral squamous cell carcinoma in Taiwan after surgical therapy: factors affecting survival.
  • PATIENTS AND METHODS: The records of 378 OSCC patients surgically treated with or without chemotherapy and radiotherapy were reviewed retrospectively.
  • Their 5-year survival in relation to age, gender, tumor site, lymph node involvement, presence of distant metastasis, staging, differentiation, and risk factors, including betel quid (BQ) chewing, cigarette smoking, and alcohol consumption, was analyzed.
  • Tumors occurred mainly at the buccal mucosa (BM) (100 of 378, 26.5%), gingiva (105 of 378, 27.8%), and tongue (103 of 378, 27.2%).
  • Neck nodal metastasis occurred frequently at the floor of the mouth (in >60% of cases), followed by the gingiva (45.7%), buccal mucosa (34%), and tongue (20.4%), whereas early distant metastasis was rare (5.3%).
  • CONCLUSIONS: Our data suggest that early treatment is the key to increasing the survival of OSCC patients.
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Alcohol Drinking / adverse effects. Areca / adverse effects. Chemotherapy, Adjuvant. Female. Humans. Linear Models. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Proportional Hazards Models. Radiotherapy, Adjuvant. Retrospective Studies. Risk Factors. Sex Factors. Smoking / adverse effects. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12856245.001).
  • [ISSN] 0278-2391
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


14. Amadio P, Ferraù F, Priolo D, Toscano G, Colina P, Mare M, Zavettieri M, La Torre F, Mesiti M, Maisano R: [Prevention and treatment of mucositis from cytotoxic chemotherapy]. Clin Ter; 2002 Mar-Apr;153(2):127-34

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prevention and treatment of mucositis from cytotoxic chemotherapy].
  • The characteristic lesions of the mucositis affect whole buccal mucosa.
  • The mucosa can suffer from direct damage of antiblastic drugs or be susceptible of microbic infections.
  • Moreover, other factors correlated to the patients as age, nutritional status, tumor type, oral hygiene and neutrophil count.
  • Up to date, there is not a standard therapy for the cure or mucositis prevention.
  • 1) altering the distribution and the excretion of drugs on the mucosa;.
  • 2) stimulating the basal cells of the mucosa;.
  • The effective oral care, dietary changes and the use of protective topical and the careful use of topical and systemic anesthetic drugs are the cornerstones of mucositis care.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Mouth Mucosa / drug effects. Stomatitis / drug therapy. Stomatitis / prevention & control
  • [MeSH-minor] Anti-Infective Agents / therapeutic use. Anti-Inflammatory Agents / therapeutic use. Humans. Infection / drug therapy. Infection / microbiology. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12078338.001).
  • [ISSN] 0009-9074
  • [Journal-full-title] La Clinica terapeutica
  • [ISO-abbreviation] Clin Ter
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Anti-Inflammatory Agents; 0 / Antineoplastic Agents
  • [Number-of-references] 88
  •  go-up   go-down


15. Noguchi M, Sakamoto N, Okumura K, Sato N, Yamada K, Isobe Y, Kato A, Oshimi K: [CD8-positive diffuse large B-cell lymphoma]. Rinsho Ketsueki; 2000 Jul;41(7):591-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In May, 1998, a 63-year-old woman was admitted for treatment of relapsed malignant lymphoma.
  • In March 1997, a diagnosis of diffuse large B-cell lymphoma(DLBL), clinical stage IIISE A, was made from a biopsy specimen of the tumor in the left buccal mucosa.
  • Because she responded to salvage chemotherapy, autologous peripheral blood stem cell transplantation was performed and complete remission was obtained.

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11020983.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / Antigens, CD8
  •  go-up   go-down


16. Ara G, Watkins BA, Zhong H, Hawthorne TR, Karkaria CE, Sonis ST, Larochelle WJ: Velafermin (rhFGF-20) reduces the severity and duration of hamster cheek pouch mucositis induced by fractionated radiation. Int J Radiat Biol; 2008 May;84(5):401-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Velafermin (rhFGF-20) reduces the severity and duration of hamster cheek pouch mucositis induced by fractionated radiation.
  • PURPOSE: Velafermin (recombinant human fibroblast growth factor-20, rhFGF-20) has been shown to reduce the severity and duration of mucositis in preclinical acute (single dose) radiation and chemotherapy/radiation models of oral mucositis.
  • EXPERIMENTAL DESIGN: Male Golden Syrian hamsters were exposed to eight doses of radiation (7.5 Gy/dose) to the cheek pouch on days 0, 1, 2, 3, 6, 7, 8 and 9 that resulted in severe mucositis.
  • Further histological analysis of resected buccal mucosa revealed improvements in epithelial tissue degradation, connective tissue degradation and inflammation severity after velafermin treatment.
  • Most notably, velafermin treatment reduced inflammatory cytokines interleukin-6 (IL-6) and tumor necrosis factor (TNF) production possibly through nuclear factor-kappaB (NF-kappaB) mediation.
  • The detection of increased NF-E2-related factor-2 (NRF-2) expression in the early onset stage of mucositis in the buccal mucosa suggested additional protective benefits from reactive oxygen species (ROS) generated as a consequence of fractionated radiation treatment.
  • CONCLUSION: Thus, velafermin provided therapeutic benefit in a hamster model of oral mucositis induced by fractionated radiation therapy.
  • [MeSH-major] Fibroblast Growth Factors / chemistry. Fibroblast Growth Factors / pharmacology. Mouth Mucosa / pathology. Radiation Injuries / drug therapy. Stomatitis / drug therapy
  • [MeSH-minor] Animals. Cheek. Cricetinae. Epithelium / radiation effects. Humans. Inflammation / radiotherapy. Interleukin-6 / biosynthesis. Male. NF-E2-Related Factor 2 / biosynthesis. NF-kappa B / biosynthesis. Tumor Necrosis Factor-alpha / biosynthesis

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18464069.001).
  • [ISSN] 0955-3002
  • [Journal-full-title] International journal of radiation biology
  • [ISO-abbreviation] Int. J. Radiat. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / FGF20 protein, human; 0 / Interleukin-6; 0 / NF-E2-Related Factor 2; 0 / NF-kappa B; 0 / Tumor Necrosis Factor-alpha; 62031-54-3 / Fibroblast Growth Factors
  •  go-up   go-down


17. Vered M, Allon I, Buchner A, Dayan D: Clinico-pathologic correlations of myofibroblastic tumors of the oral cavity. II. Myofibroma and myofibromatosis of the oral soft tissues. J Oral Pathol Med; 2007 May;36(5):304-14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinico-pathologic correlations of myofibroblastic tumors of the oral cavity. II. Myofibroma and myofibromatosis of the oral soft tissues.
  • BACKGROUND: Myofibroma is a solitary benign tumor of myofibroblasts.
  • The clinico-pathologic correlations of myofibroma/myofibromatosis confined only to oral soft tissues were analyzed.
  • METHODS: In the English language literature, 41 myofibroma and 12 myofibromatosis cases involving the oral soft tissues were found.
  • RESULTS: Age at time of diagnosis of oral mucosa myofibroma ranged from birth to 70 years (mean 21.7 years), considerably higher than myofibroma in other parts of the body.
  • Common sites were the tongue (32%) and buccal mucosa (18%).
  • Treatment was local excision, either complete (n = 13) or partial (n = 3), wide excision (n = 4), surgery, and chemotherapy (n = 1).
  • Myofibromatosis involving oral soft tissues was diagnosed at birth in nine (75%) patients, within the first year in two, and as a young adult in one.
  • Histologically, oral mucosa myofibroma/myofibromatosis appearance agreed with findings in the literature.
  • CONCLUSIONS: Myofibroma should be included in the clinical differential diagnosis of masses of the oral soft tissues, especially in the tongue and buccal mucosa of children and adolescents.
  • Histological differential diagnosis includes benign and malignant spindle-shaped lesions.
  • Treatment of choice is local excision.
  • [MeSH-major] Lip Neoplasms / pathology. Mouth Mucosa / pathology. Myofibromatosis / pathology. Neoplasms, Muscle Tissue / pathology. Tongue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Diagnosis, Differential. Female. Humans. Infant. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Oral Pathol Med. 2008 Jan;37(1):62 [18154581.001]
  • (PMID = 17448141.001).
  • [ISSN] 0904-2512
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Denmark
  • [Number-of-references] 54
  •  go-up   go-down


18. Ispenkova NE, Shental' VV, Panin MG, Liubaev VL, Delidova EV: [Comparative assessment of 5-year survival with cancer of the buccal mucosa treated by different methods]. Stomatologiia (Mosk); 2001;80(6):42-4
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparative assessment of 5-year survival with cancer of the buccal mucosa treated by different methods].
  • We analyzed case histories of 495 patients with oral cancer treated in the Head and Neck Tumor Clinic of the Russian Cancer Research Center RAMS from 1985 to 1998.
  • 88 patients were included in the study out of which 50 reserved combined (radiotherapy + surgery) and 38--complex (chemotherapy + radiotherapy + surgery) treatment.
  • On assessing the clinical results we got the following results: after combined treatment 5-year survival was 45.9 +/- 7.0%, while after the complex method--37.2 +/- 7.8%.
  • The inclusion of chemotherapy to the treatment does not significantly influence long-term results.
  • [MeSH-major] Mouth Mucosa. Mouth Neoplasms / mortality. Mouth Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Survival Analysis. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11881462.001).
  • [ISSN] 0039-1735
  • [Journal-full-title] Stomatologii︠a︡
  • [ISO-abbreviation] Stomatologiia (Mosk)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  •  go-up   go-down


19. Lu JY, Chang CC, Chang YL: Adrenal lymphoma and Addison's disease: report of a case. J Formos Med Assoc; 2002 Dec;101(12):854-8
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 80-year-old man presented with nausea, anorexia, weight loss, and hyperpigmentation of the skin and buccal mucosa.
  • Computerized tomography (CT) of the adrenal glands revealed a small right adrenal tumor.
  • His family refused to allow percutaneous or surgical biopsy to determine the nature of the tumor.
  • However, about 1 year later, dizziness, fever, night sweats, and edema of the lower legs developed, and adrenal CT scanning revealed that the left adrenal gland had enlarged and now exceeded the size of the right one.
  • Chemotherapy was given, but the disease still progressed and the patient died 4 months after diagnosis.
  • Primary adrenal lymphoma should be considered in the differential diagnosis of Addison's disease, even if only slight enlargement of the adrenal glands is found initially.

  • Genetic Alliance. consumer health - Addison's Disease.
  • MedlinePlus Health Information. consumer health - Addison Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12632819.001).
  • [ISSN] 0929-6646
  • [Journal-full-title] Journal of the Formosan Medical Association = Taiwan yi zhi
  • [ISO-abbreviation] J. Formos. Med. Assoc.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


20. Tucci R, Aburad De Carvalhosa A, Anunciação G, Daumas Nunes F, Dos Santos Pinto D Jr: Late diagnosis of a primary oral malignant melanoma: a case report. Minerva Stomatol; 2010 Jan-Feb;59(1-2):55-9
MedlinePlus Health Information. consumer health - Melanoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late diagnosis of a primary oral malignant melanoma: a case report.
  • Eighty percent of the cases are located on the palate and maxillary gingiva, with the remainder found on the mandibular gingiva, buccal mucosa, tongue, and floor of the mouth.
  • OMM are highly aggressive with the tendency to metastasize and invade the surrounding tissues more readily than other oral malignancies.
  • The usual therapeutic approach for OMM is surgical excision of the primary tumor, supplemented by radiotherapy, with chemotherapy and immunotherapy serving as adjuvant.
  • Palpation revealed a painless soft tissue arising in maxillary gingiva, extending to the palate and vestibular mucosa.
  • The patient underestimated his symptoms and look for treatment after a substantial growth of the lesion.
  • This is an example of how a delayed detection affects the prognosis of OMM.
  • [MeSH-major] Gingival Neoplasms / diagnosis. Melanoma / diagnosis
  • [MeSH-minor] Adult. Delayed Diagnosis. Denial (Psychology). Fatal Outcome. Humans. Male. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20212410.001).
  • [ISSN] 0026-4970
  • [Journal-full-title] Minerva stomatologica
  • [ISO-abbreviation] Minerva Stomatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


21. Harada K, Sato M, Ueyama Y, Nagayama M, Hamakawa H, Nagahata S, Yoshimura Y, Osaki T, Ryoke K, Oral Cancer Study Group of Chugoku-Shikoku: Multi-institutional phase II trial of S-1 in patients with oral squamous cell carcinoma. Anticancer Drugs; 2008 Jan;19(1):85-90
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The sites of the primary tumor were the gingiva (n=18), the tongue (n=12), the palate (n=5), the oral floor (n=4), the buccal mucosa (n=1), and the labial mucosa (n=1).
  • A median of two cycles of treatment (range, 1-5) was administered.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Dose-Response Relationship, Drug. Drug Combinations. Female. Follow-Up Studies. Humans. Male. Middle Aged. Survival Analysis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Oral squamous cell carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043133.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


22. Dahllöf G, Borgström P, Lundell G, Jacobsson H, Kogner P: Severe oral mucositis after therapeutic administration of [131I]MIBG in a child with neuroblastoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Oct;92(4):420-3
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Severe oral mucositis after therapeutic administration of [131I]MIBG in a child with neuroblastoma.
  • OBJECTIVE: The purpose of this report is to document a newly encountered oral side effect of targeted radiotherapy with iodine 131-metaiodobenzylguanidine ([(131)I]MIBG) in the treatment of neuroblastoma.
  • After completion of chemotherapy, the tumor showed no signs of regression; treatment with 3700 MBq [(131)I]MIBG was therefore decided on, 8 months after diagnosis.
  • RESULTS: Fourteen days after infusion of MIBG, severe oral mucositis was diagnosed, with a generalized erythema involving the mucous membranes of the hard and soft palate, buccal mucosa, and upper and lower lips.
  • [MeSH-major] 3-Iodobenzylguanidine / adverse effects. Abdominal Neoplasms / radiotherapy. Mouth Mucosa / radiation effects. Neuroblastoma / radiotherapy. Stomatitis / etiology

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11598577.001).
  • [ISSN] 1079-2104
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 35MRW7B4AD / 3-Iodobenzylguanidine
  •  go-up   go-down


23. Nishihara K, Nozoe E, Hirayama Y, Miyawaki A, Semba I, Nakamura N: A case of small cell carcinoma in the buccal region. Int J Oral Maxillofac Surg; 2009 Sep;38(9):1000-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of small cell carcinoma in the buccal region.
  • Small cell carcinoma (SCC) in the head and neck region is an extremely rare high-grade malignant tumor.
  • The authors report a case of an SCC occurring in the left buccal region.
  • An 85-year-old man exhibited left cheek swelling that rapidly increased in size.
  • Histopathological examination revealed invasive growth of an SCC into the musculo-adipose tissue.
  • Immunohistochemically, the tumor cells were positive for cytokeratin (AE1/AE3), neuron-specific enolase (NSE) and CD56, but negative for cytokeratin 20.
  • The patient received chemotherapy and radiotherapy, which resulted in marked regression of the tumor.
  • The serum levels of NSE and pro-gastrin-releasing peptide (pro-GRP) increased and multiple metastases of the tumor occurred 1 month after surgery.
  • SCCs tend to exhibit aggressive invasion and metastasis so chemotherapy for the whole body is recommended to prevent dissemination of the tumor cells.
  • Serum levels of NSE and pro-GRP are considered to be useful tumor markers for understanding the status of the tumor and the clinical symptoms.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Cheek / pathology. Mouth Mucosa / pathology. Mouth Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Biomarkers, Tumor / blood. Combined Modality Therapy. Fatal Outcome. Humans. Male. Peptide Fragments / blood. Phosphopyruvate Hydratase / blood. Recombinant Proteins / blood

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19464148.001).
  • [ISSN] 1399-0020
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Peptide Fragments; 0 / Recombinant Proteins; 0 / pro-gastrin-releasing peptide (31-98); EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


24. Kleikamp S, Böhm M, Frosch P, Brinkmeier T: [Acanthosis nigricans, papillomatosis mucosae and "tripe palms" in a patient with metastasized gastric carcinoma]. Dtsch Med Wochenschr; 2006 May 26;131(21):1209-13
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Acanthosis nigricans, Papillomatosis mucosae und "tripe palms" bei einem Patienten mit metastasiertem Magenkarzinom.
  • HISTORY AND CLINICAL FINDINGS: A 48-year-old obese man presented with thickening, coarseness and hyperpigmentation of the skin, especially of the intertriginous areas, papillomatous to verrucous lesions of the lips and buccal oral mucosa, and hyperkeratosis of the palms ("tripe palms") and soles.
  • Increased levels of tumor markers CA 19-9 (141100 U/ml), CA 72-4 (755 U/ml) and CEA (189 ng/ml) were found in the serum.
  • At the time of diagnosis the tumor had already metastasized to perigastric and peripancreatic lymph nodes with peritoneal carcinosis.
  • TREATMENT AND COURSE: Since a curative resection was impossible a gastrojejunostomy was carried out.
  • After this the patient received several courses of chemotherapy according to different schemes.
  • Serum tumor marker levels and cutaneous signs regressed several times.
  • CONCLUSIONS: Marked acanthosis nigricans -- especially when associated with further cutaneous markers of malignancy, e.g. mucocutaneous papillomatosis or so-called tripe palms -- calls for thorough search for malignant tumor, also if metabolic or endocrinological abnormalities co-exist.
  • [MeSH-major] Carcinoma, Signet Ring Cell / diagnosis. Carcinoma, Signet Ring Cell / secondary. Skin Diseases / etiology. Stomach Neoplasms / diagnosis. Stomach Neoplasms / pathology
  • [MeSH-minor] Acanthosis Nigricans / diagnosis. Acanthosis Nigricans / etiology. Antigens, Tumor-Associated, Carbohydrate / blood. Biomarkers, Tumor / blood. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Fatal Outcome. Humans. Immunohistochemistry. Keratoderma, Palmoplantar / diagnosis. Keratoderma, Palmoplantar / etiology. Lymphatic Metastasis. Male. Middle Aged. Mouth Neoplasms / diagnosis. Mouth Neoplasms / etiology. Obesity / complications. Papilloma / diagnosis. Papilloma / etiology. Peritoneal Neoplasms / secondary. Receptor, Melanocortin, Type 1 / analysis

  • Genetic Alliance. consumer health - Acanthosis Nigricans.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16721709.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / CA-72-4 antigen; 0 / Carcinoembryonic Antigen; 0 / Receptor, Melanocortin, Type 1
  •  go-up   go-down


25. Iwabuchi H, Takamori K, Honma H, Asanami S, Tanaka Y: [A case of mandibular gingival cancer T4N0M0 which markedly responded to a combined therapy of nedaplatin with 5-fluorouracil]. Gan To Kagaku Ryoho; 2001 Sep;28(9):1273-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of mandibular gingival cancer T4N0M0 which markedly responded to a combined therapy of nedaplatin with 5-fluorouracil].
  • We recently experienced a case of mandibular gingival cancer T4N0M0 which markedly responded to a combination therapy of nedaplatin (254-S) with 5-fluorouracil (5-FU).
  • Biopsy revealed a moderately differentiated squamous cell carcinoma which extended to the mandible, mandibular gingiva, buccal mucosa, half tongue and oral floor on the left side of the face.
  • As a neoadjuvant chemotherapy (NAC), 254-S at a dose of 100 mg/m2 was intravenously administered on day 1, while 5-FU at a dose of 700 mg/m2/day was intravenously administered from day 1 to 5 in succession.
  • Pathological examination of the extracted tissues showed tumor cells in the tongue only, indicating an excellent effect of this combination therapy of 254-S and 5-FU.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Gingival Neoplasms / drug therapy
  • [MeSH-minor] Aged. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Male. Mandible. Organoplatinum Compounds / administration & dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11579639.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


26. Yücel A, Cinar C, Aydin Y, Senyuva C, Güzel Z, Cetinkale O, Altintaŝ M: Malignant tumors requiring maxillectomy. J Craniofac Surg; 2000 Sep;11(5):418-29
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary site of tumor was adjacent skin in 53%, maxillary sinus or maxilla in 20%, palate and alveolar arch in 13%, lip and buccal mucosa in 13%, and mandible in 1% of the cases.
  • Postoperative radiotherapy was performed in 32 patients and combined radiotherapy and chemotherapy in 12 patients.
  • Resection of the tumor with free surgical margins and appropriate evaluation of the surgical defect for the most suitable reconstruction are the mainstays of treatment of the midfacial tumors.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Basal Cell / surgery. Carcinoma, Squamous Cell / surgery. Chemotherapy, Adjuvant. Disease-Free Survival. Facial Neoplasms / surgery. Female. Humans. Lip Neoplasms / surgery. Male. Mandible / surgery. Mandibular Neoplasms / surgery. Maxillary Neoplasms / surgery. Maxillary Sinus Neoplasms / surgery. Middle Aged. Mouth Neoplasms / surgery. Neck Dissection. Neoplasm Recurrence, Local / surgery. Orbit Evisceration. Palatal Neoplasms / surgery. Palatal Obturators. Radiotherapy, Adjuvant. Retrospective Studies. Skin Neoplasms / surgery. Skin Transplantation / methods. Surgical Flaps

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11314064.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Rosell R, Taron M, Camps C, López-Vivanco G: Influence of genetic markers on survival in non-small cell lung cancer. Drugs Today (Barc); 2003 Oct;39(10):775-86
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cisplatin or carboplatin is commonly used with gemcitabine, docetaxel, paclitaxel or vinorelbine as chemotherapy doublets in the treatment of advanced non-small cell lung cancer.
  • This lack of evidence for improvement in survival with any chemotherapy regimen has created a tabula rasa in which no more large randomized trials should be conducted with out including a genetic analysis.
  • Patients see survival as their major concern, and other considerations, such as cost of treatment and qualify of life, are relegated to lower positions.
  • For a long time, ERCC1 mRNA levels have been known to correlate with DNA repair capacity in various tissues.
  • Levels of DNA cisplatin adducts in peripheral blood and buccal mucosa cells predict chemotherapy response, and high ERCC1 mRNA levels have been related to chemoresistance in ovarian cancer and in malignant lymphocytes from chronic lymphocytic leukemia.
  • An ongoing customized ERCC1-based chemotherapy trial has been established on this knowledge.
  • At the preclinical level, ERCC1 and XPD mRNA expression correlate with each other, and overexpression of XPD causes selective cisplatin resistance in human tumor cell lines.
  • In our experience, time to disease progression is significantly higher in gemcitabine/cisplatin-treated patients with the Lys751Gln genotype (9.6 months) than in those with the Lys751Lys genotype (4.2 months; p = 0.03).
  • This highlights the possibilities of individually tailored chemotherapy.
  • Patients with Lys751Lys had a longer time to progression.
  • At least 50% of non-small cell lung cancer patients harbor Lys751Lys and can benefit from docetaxel/ cisplatin treatment.
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Antineoplastic Agents / therapeutic use. Cisplatin / pharmacology. Cisplatin / therapeutic use. Clinical Trials as Topic. DNA Adducts / metabolism. DNA Repair. Drug Resistance, Neoplasm / genetics. Genetic Markers. Humans. Polymorphism, Genetic. Proteins / genetics. Ribonucleotide Reductases / genetics. Survival Rate. Xeroderma Pigmentosum Group D Protein

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14668933.001).
  • [ISSN] 1699-3993
  • [Journal-full-title] Drugs of today (Barcelona, Spain : 1998)
  • [ISO-abbreviation] Drugs Today
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA Adducts; 0 / DNA-Binding Proteins; 0 / Genetic Markers; 0 / Proteins; 0 / Transcription Factors; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; EC 1.17.4.- / Ribonucleotide Reductases; EC 3.6.4.- / DNA Helicases; EC 3.6.4.12 / Xeroderma Pigmentosum Group D Protein; EC 5.99.- / ERCC2 protein, human; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 54
  •  go-up   go-down


28. Kok SH, Hong CY, Kuo MY, Lee CH, Lee JJ, Lou IU, Lee MS, Hsiao M, Lin SK: Comparisons of norcantharidin cytotoxic effects on oral cancer cells and normal buccal keratinocytes. Oral Oncol; 2003 Jan;39(1):19-26
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparisons of norcantharidin cytotoxic effects on oral cancer cells and normal buccal keratinocytes.
  • In this study, multi-parameter assessments of morphological alterations, clonogenic efficiency, cell growth curves, DNA synthesis, and DNA strand break were employed to determine and compare the cytotoxic effects of NCTD on oral cancer KB cell line and normal buccal keratinocytes.
  • Normal buccal keratinocytes were more resistant to NCTD induced cytotoxicity.
  • The IC(50) of 24 h NCTD treatment for KB and keratinocytes were 15.06 and 216.29 microg/ml, respectively with a keratinocyte/KB selective index of 14.36.
  • In addition, inhibition of colony formation was noted in KB cells even when exposed to low concentration of drug (5 microg/ml) for a short period of time (6 h).
  • The underlying mechanisms of the differential actions of NCTD on these two cell types are worthy of further investigations.
  • [MeSH-major] Bicyclo Compounds, Heterocyclic / therapeutic use. Mouth Neoplasms / drug therapy
  • [MeSH-minor] Cell Division / drug effects. DNA Damage. DNA, Neoplasm / biosynthesis. Dose-Response Relationship, Drug. Drug Screening Assays, Antitumor. Humans. Keratinocytes / drug effects. Mouth Mucosa. Tumor Cells, Cultured / drug effects

  • Genetic Alliance. consumer health - Oral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12457717.001).
  • [ISSN] 1368-8375
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Bicyclo Compounds, Heterocyclic; 0 / DNA, Neoplasm; 5442-12-6 / norcantharidin
  •  go-up   go-down


29. Chen HM, Chen CT, Yang H, Lee MI, Kuo MY, Kuo YS, Wang YP, Tsai T, Chiang CP: Successful treatment of an extensive verrucous carcinoma with topical 5-aminolevulinic acid-mediated photodynamic therapy. J Oral Pathol Med; 2005 Apr;34(4):253-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of an extensive verrucous carcinoma with topical 5-aminolevulinic acid-mediated photodynamic therapy.
  • Our recent study found that a new topical 5-aminolevulinic acid-mediated photodynamic therapy (ALA-PDT) protocol composed of multiple 3-min fractionated irradiations with a light emitting diode (LED) red light at 635 +/- 5 nm for a total of 1000 s (fluence rate: 100 mW/cm(2); light exposure dose: 100 J/cm(2)) after topical application of 20% ALA for 1.5 or 2 h can be used successfully for the treatment of oral verrucous hyperplasia.
  • In this case report, we tested the efficacy of this new treatment protocol of ALA-PDT for an extraoral verrucous carcinoma (VC) lesion at the right mouth angle and an intraoral VC lesion at the right buccal mucosa of a 56-year-old male areca quid chewer and smoker.
  • The extraoral tumor was cleared after six treatments of topical ALA-PDT and the intraoral tumor showed complete regression after 22 treatments of topical ALA-PDT.
  • We suggest that PDT using a topical application of 20% ALA followed by multiple 3-min fractionated irradiations with an LED red light is also an effective and successful treatment modality for VC.
  • [MeSH-major] Aminolevulinic Acid / therapeutic use. Carcinoma, Verrucous / drug therapy. Lip Neoplasms / drug therapy. Mouth Neoplasms / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use
  • [MeSH-minor] Administration, Topical. Dose Fractionation. Follow-Up Studies. Humans. Male. Middle Aged. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15752262.001).
  • [ISSN] 0904-2512
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


30. Tan AR, Yang X, Hewitt SM, Berman A, Lepper ER, Sparreboom A, Parr AL, Figg WD, Chow C, Steinberg SM, Bacharach SL, Whatley M, Carrasquillo JA, Brahim JS, Ettenberg SA, Lipkowitz S, Swain SM: Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol; 2004 Aug 1;22(15):3080-90
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor.
  • PURPOSE: To evaluate changes in epidermal growth factor receptor (EGFR) phosphorylation and its downstream signaling in tumor and surrogate tissue biopsies in patients with metastatic breast cancer treated with erlotinib, an EGFR tyrosine kinase inhibitor, and to assess relationships between biomarkers in tumor and normal tissues and between biomarkers and pharmacokinetics.
  • Ki67, EGFR, phosphorylated EGFR (pEGFR), phosphorylated mitogen-activated protein kinase (pMAPK), and phosphorylated AKT (pAKT) in 15 paired tumor, skin, and buccal mucosa biopsies (at baseline and after 1 month of therapy) were examined by immunohistochemistry and analyzed quantitatively.
  • RESULTS: The stratum corneum layer and Ki67 in keratinocytes of the epidermis in 15 paired skin biopsies significantly decreased after treatment (P = .0005 and P = .0003, respectively).
  • In the EGFR-positive tumor, pEGFR, pMAPK, and pAKT were reduced after treatment.
  • Paradoxically, pEGFR was increased in EGFR-negative tumors post-treatment (P = .001).
  • Although markers were reduced in surrogate and tumor tissues in the patient with EGFR-positive tumor, no apparent associations were observed in patients with EGFR-negative tumor.
  • CONCLUSION: Erlotinib has inhibitory biologic effects on normal surrogate tissues and on an EGFR-positive tumor.
  • The lack of reduced tumor proliferation may be attributed to the heterogeneous expression of receptor in the EGFR-positive patient and absence of target in this cohort of heavily pretreated patients.
  • [MeSH-minor] Administration, Oral. Biomarkers / analysis. Endpoint Determination. Erlotinib Hydrochloride. Female. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Mouth Mucosa / metabolism. Neoplasm Metastasis. Phosphorylation. Pilot Projects. Signal Transduction / drug effects. Skin / metabolism. Tomography, Emission-Computed


31. Inagi K, Takahashi H, Okamoto M, Nakayama M, Makoshi T, Nagai H: Treatment effects in patients with squamous cell carcinoma of the oral cavity. Acta Otolaryngol Suppl; 2002;(547):25-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment effects in patients with squamous cell carcinoma of the oral cavity.
  • Tumor localization was as follows: cancer of the tongue, n = 161; cancer of the oral floor, n = 28; cancer of the hard palate, n = 12; cancer of the buccal mucosa, n = 11; and cancer of the gingiva, n = 9.
  • In order to compare the effect of different treatments, three major treatment groups were defined, namely a surgery group, a radiotherapy group and a combination treatment group.
  • Five-year cumulative survival rates showed significant differences between stage classifications (stage I = 91%, stage II = 73%, stage III = 63%, stage IV = 47%; p < 0.01) but not between tumor sites.
  • No significant difference in regional control rates was observed between the treatment groups.
  • The 5-year survival rate for patients with cervical recurrences after primary tumor resection was 70% (n = 15).
  • In contrast, the 5-year survival rate for patients with both primary tumor resection and neck dissection was 74% (n = 14) but no significant difference was observed between these 2 groups.
  • [MeSH-major] Antineoplastic Protocols. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / therapy. Mouth / drug effects. Mouth / radiation effects. Mouth Neoplasms / mortality. Mouth Neoplasms / therapy. Outcome Assessment (Health Care)
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Severity of Illness Index. Survival Rate


32. Yamagata K, Onizawa K, Kojima H, Yoshida H: Treatment of localized oral MALT lymphoma by rituximab: a case report. Oral Maxillofac Surg; 2008 Dec;12(4):227-30
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of localized oral MALT lymphoma by rituximab: a case report.
  • INTRODUCTION: Extranodal marginal zone B cell lymphoma of mucosa-associated lymphoma tissue (MALT) among intraoral malignant lymphomas is very rare.
  • Moreover, no case of oral MALT lymphoma treated with monoclonal antibody therapy has been reported.
  • DISCUSSION: We describe a case of MALT lymphoma arising in an 87-year-old Japanese woman under the buccal mucosa that was successfully treated with rituximab, a chimeric monoclonal antibody against the B cell-specific antigen CD20.
  • Currently, 5 months after completing treatment, the patient is alive and has partial regression of the tumor.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Immunologic Factors / therapeutic use. Lymphoma, B-Cell, Marginal Zone / drug therapy. Mouth Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2002 Feb;33(2):153-7 [11957138.001]
  • [Cites] Eur J Dermatol. 1998 Jul-Aug;8(5):350-2 [9683860.001]
  • [Cites] Scand J Urol Nephrol. 1998 May;32(3):234-6 [9689708.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1993 Dec;18(6):528-32 [8877235.001]
  • [Cites] J Ultrasound Med. 1997 Sep;16(9):615-7 [9321782.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Mar;99(3):303-10 [15716836.001]
  • [Cites] Arthritis Rheum. 1999 Aug;42(8):1765-72 [10446879.001]
  • [Cites] J Clin Oncol. 1997 Apr;15(4):1624-30 [9193362.001]
  • [Cites] J Oral Pathol Med. 2006 May;35(5):314-6 [16630297.001]
  • [Cites] Cancer. 2003 May 1;97(9):2236-41 [12712477.001]
  • [Cites] Pathol Int. 2006 Jun;56(6):331-5 [16704497.001]
  • [Cites] Blood. 2003 Oct 15;102(8):2741-5 [12842999.001]
  • [Cites] Ann Intern Med. 1978 Dec;89(6):888-92 [102228.001]
  • [Cites] Cancer. 1984 Jun 1;53(11):2515-24 [6424928.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Nov;92(5):519-25 [11709688.001]
  • [Cites] Br J Oral Maxillofac Surg. 2004 Feb;42(1):28-32 [14706295.001]
  • [Cites] Med Oral Patol Oral Cir Bucal. 2004 Nov-Dec;9(5):461-3; 459-61 [15580125.001]
  • [Cites] J Oral Pathol Med. 1998 May;27(5):229-32 [9682987.001]
  • (PMID = 18830723.001).
  • [ISSN] 1865-1550
  • [Journal-full-title] Oral and maxillofacial surgery
  • [ISO-abbreviation] Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Immunologic Factors; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


33. Fuwa N, Kodaira T, Furutani K, Tachibana H, Nakamura T: A new method of selective intra-arterial infusion therapy via the superficial temporal artery for head and neck cancer. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2008 Jun;105(6):783-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new method of selective intra-arterial infusion therapy via the superficial temporal artery for head and neck cancer.
  • STUDY DESIGN: This study included 92 patients who were treated by this combination therapy between May 1999 and December 2004.
  • Primary tumor sites included the tongue in 73 patients, base of the tongue in 6 patients, floor of mouth in 4 patients, buccal mucosa in 4 patients, and other sites in 5 patients.
  • In 4 patients, the catheter fell out of the selected artery during treatment.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carboplatin / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Radiography, Interventional / methods. Tongue Neoplasms / drug therapy

  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18206406.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 8UQ3W6JXAN / nedaplatin; BG3F62OND5 / Carboplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down


34. Ko SY, Chang KW, Lin SC, Hsu HC, Liu TY: The repressive effect of green tea ingredients on amyloid precursor protein (APP) expression in oral carcinoma cells in vitro and in vivo. Cancer Lett; 2007 Jan 8;245(1-2):81-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a hamster model of N-methyl-N-benzylnitrosamine (MBN)-induced oral carcinogenesis, the incidence of buccal pouch (HBP) carcinomas in MBN-treated hamsters (17.8+/-7.5) was significantly higher than MBN-treated hamsters given tea (10.8+/-3.9) (P<0.05).
  • [MeSH-major] Amyloid beta-Protein Precursor / genetics. Carcinoma, Squamous Cell / drug therapy. Mouth Neoplasms / drug therapy. Plant Preparations / pharmacology. Tea / chemistry
  • [MeSH-minor] Animals. Blotting, Western. Catechin / analogs & derivatives. Catechin / pharmacology. Cell Line, Tumor. Cricetinae. Disease Models, Animal. Dose-Response Relationship, Drug. Gene Expression Regulation, Neoplastic / drug effects. Humans. Immunohistochemistry. Male. Mesocricetus. Mouth Mucosa / drug effects. Mouth Mucosa / metabolism. Mouth Mucosa / pathology. Phytotherapy. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Green tea .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16458426.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Amyloid beta-Protein Precursor; 0 / Plant Preparations; 0 / RNA, Messenger; 0 / Tea; 8R1V1STN48 / Catechin; BQM438CTEL / epigallocatechin gallate
  •  go-up   go-down


35. Chao TJ: Adalimumab in the management of cutaneous and oral lichen planus. Cutis; 2009 Dec;84(6):325-8
Genetic Alliance. consumer health - Oral lichen planus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lichen planus (LP) is a common, chronic, inflammatory dermatosis that may involve the skin as well as oral and genital mucosa.
  • Characterized by distinctive purplish papules often featuring white reticular scale, LP commonly is resistant to treatment.
  • My patient presented with extensive, violaceous, and lacelike whitish lesions on the distal extremities, including the hands and feet, and the vulva.
  • Approximately 10% to 12% of her body surface area (BSA) was involved, and her condition became progressively worse over time, with thick plaques developing on the buccal mucosa and tongue.
  • After several conventional therapies failed, the patient underwent treatment with adalimumab, a tumor necrosis factor (TNF) antagonist.
  • Additional studies are warranted to investigate the efficacy and safety of adalimumab for the treatment of LP.
  • [MeSH-major] Anti-Inflammatory Agents / therapeutic use. Antibodies, Monoclonal / therapeutic use. Lichen Planus / drug therapy
  • [MeSH-minor] Adalimumab. Antibodies, Monoclonal, Humanized. Female. Humans. Lichen Planus, Oral / drug therapy. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20166574.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; FYS6T7F842 / Adalimumab
  •  go-up   go-down


36. Manoharan S, Panjamurthy K, Balakrishnan S, Vasudevan K, Vellaichamy L: Circadian time-dependent chemopreventive potential of withaferin-A in 7,12-dimethylbenz[a]anthracene-induced oral carcinogenesis. Pharmacol Rep; 2009 Jul-Aug;61(4):719-26
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circadian time-dependent chemopreventive potential of withaferin-A in 7,12-dimethylbenz[a]anthracene-induced oral carcinogenesis.
  • Circadian time-dependent treatment with chemotherapeutic drugs (chronotherapy) optimizes the therapeutic index by maximizing treatment efficacy and minimizing toxicity.
  • The circadian time-dependent chemopreventive and anti-lipid peroxidative efficacy of withaferin-A in 7,12-dimethylbenz[a]anthracene (DMBA)-induced hamster buccal pouch carcinogenesis was investigated in the present study.
  • We induced oral squamous cell carcinoma in the buccal pouches of golden Syrian hamsters during the day (4:00, 8:00, 12:00, 16:00, 20:00 and 24:00) by application of DMBA three times per week for 14 weeks.
  • The circadian time-dependent tumor incidence, volume and burden were observed in hamsters treated with either DMBA alone or DMBA + withaferin-A.
  • The circadian pattern of lipid peroxidation by-products, as measured by the formation of thiobarbituric acid reactive substances (TBARS) and enzymatic antioxidants [superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GPx)], was also analyzed in the buccal mucosa of DMBA-treated hamsters.
  • We found the highest incidence of tumor formation at 24.00 h in hamsters treated with DMBA alone as compared to other experimental groups.
  • Oral (po) administration of withaferin-A (20 mg/kg) completely prevented the formation of tumors between 8.00 h and 12.00 h and synchronized the status of lipid peroxidation and antioxidants in the buccal mucosa of hamsters treated with DMBA alone.
  • Also, oral administration of withaferin-A to DMBA-treated animals significantly reduced the formation of tumors and synchronized the status of lipid peroxidation and antioxidants in the rest of the time intervals.
  • Our study thus suggests that withaferin-A has significant chemopreventive and anti-lipid peroxidative potential in DMBA-induced oral carcinogenesis, probably by interfering with DMBA-induced abnormal cell proliferation in the buccal mucosa.
  • [MeSH-major] 9,10-Dimethyl-1,2-benzanthracene / toxicity. Antineoplastic Agents, Phytogenic / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Circadian Rhythm / drug effects. Ergosterol / analogs & derivatives. Mouth Neoplasms / drug therapy
  • [MeSH-minor] Animals. Cricetinae. Male. Mesocricetus. Phytotherapy / methods. Plant Extracts / administration & dosage. Plant Extracts / isolation & purification. Plant Extracts / therapeutic use. Plant Roots. Withanolides

  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. ERGOSTEROL .
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19815955.001).
  • [ISSN] 1734-1140
  • [Journal-full-title] Pharmacological reports : PR
  • [ISO-abbreviation] Pharmacol Rep
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Plant Extracts; 0 / Withanolides; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; L6DO3QW4K5 / withaferin A; Z30RAY509F / Ergosterol
  •  go-up   go-down


37. Bartelink H, Begg AC, Martin JC, van Dijk M, Moonen L, van 't Veer LJ, Van de Vaart P, Verheij M: Translational research offers individually tailored treatments for cancer patients. Cancer J Sci Am; 2000 Jan-Feb;6(1):2-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translational research offers individually tailored treatments for cancer patients.
  • In a phase II dose escalation trial with concomitant radiotherapy and daily cisplatin in lung cancer, we found that patients with high DNA adduct levels measured in the buccal mucosa had a much higher survival rate than patients with a low or undetectable amount of cisplatin-DNA adducts.
  • The use of this assay may therefore allow the selection of individual patients for concomitant treatment with cisplatin and radiotherapy, as has been shown to be effective in randomized trials in patients with lung, head and neck, and cervix malignancies.
  • To predict the response to radiation treatment, assays have been developed for tumor growth potential by measuring the labeling index after intravenous injection of IdUrd or by estimating cyclin D1 expression.
  • Pretreatment levels of apoptosis may also be helpful in predicting treatment outcome, although the data so far show inconsistent results.
  • We have recently shown that alkyllysophospholipids, which inhibit mitogenic signaling, induce apoptosis in a variety of tumor cell lines.
  • This type of a signaling-based intervention could form the basis for new therapeutic strategies.
  • The role of hormonal therapy in breast cancer patients, both in an adjuvant setting and for the treatment of disseminated disease, is becoming increasingly important.
  • These assays are simply examples, illustrating how clinicians could improve the therapeutic outcome for their patients by implementing knowledge obtained in the laboratory in clinical decision making.
  • With further optimization of these assays, this holds the promise for the future that the treatment for each patient can be tailored rationally to the biology of the individual.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Neoplasms / drug therapy. Research Design
  • [MeSH-minor] Biomarkers, Tumor / analysis. Combined Modality Therapy. DNA Adducts. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10696731.001).
  • [ISSN] 1081-4442
  • [Journal-full-title] The cancer journal from Scientific American
  • [ISO-abbreviation] Cancer J Sci Am
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / DNA Adducts; 0 / cisplatin-DNA adduct; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 66
  •  go-up   go-down






Advertisement